|
Wednesday, 19 October 2011 01:27 |
|
Data from Cardiovascular Systems’ (CSI) (Nasdaq: CSII) Predator 360° prospective single-center clinical study titled, Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non-Compliant Plaque to Deliver Durable Long-Term Results, presented today affirmed the procedural safety and efficacy, as well as the long-term durability, of the Predator 360® PAD System in treating peripheral arterial disease (PAD), or blockages in leg arteries.
|
|
Read more...
|
|
Tuesday, 18 October 2011 05:30 |
|
The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study.
|
|
Read more...
|
|
Tuesday, 18 October 2011 05:26 |
|
Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc. ("TGRD U.S."), and Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe"), announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.
|
|
Read more...
|
|
Monday, 17 October 2011 20:25 |
|
Dendreon Corporation (Nasdaq: DNDN) today announced that the company has begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon’s investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer.
|
|
Read more...
|
|
Monday, 17 October 2011 20:22 |
|
ParaPRO, LLC, announced that researchers have presented data showing the effectiveness of Natroba™ (spinosad) Topical Suspension, 0.9% against head lice and nits following one treatment without nit combing.
|
|
Read more...
|
|
Saturday, 15 October 2011 16:51 |
|
InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections.
|
|
Read more...
|
|
Saturday, 15 October 2011 16:48 |
|
ViroMed Co., Ltd. (KOSDAQ: 084990) today announced that the results of the Phase I/II study on its diabetic neuropathy therapeutic drug (VM202-DPN) were presented at ‘BIO KOREA 2011 Conference & Exhibition’ held at COEX (Seoul, Korea) from 28th to 30th Sept., and showed the world the possibility of an innovative treatment method completely different from the currently available diabetic neuropathy treatments.
|
|
Read more...
|
|
Friday, 14 October 2011 01:43 |
|
Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter’s investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.
|
|
Read more...
|
|
Friday, 14 October 2011 01:40 |
|
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that a poster describing results from a prospective three year clinical trial of its non-surgical Renessa® treatment for stress urinary incontinence (SUI) in women was presented at two professional society meetings in September 2011: the annual national Scientific Meeting of the American Urogynecologic Society (AUGS) and the South Central Section of the American Urological Association.
|
|
Read more...
|
|
Thursday, 13 October 2011 01:26 |
|
Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -
Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).
|
|
Read more...
|
|
|
Tuesday, 18 October 2011 05:33 |
|
Max Neeman International is the only CRO in India to manage hemophilia trials according to the Clinical Trials Registry-India (CTRI).
|
|
Read more...
|
|
Tuesday, 18 October 2011 05:28 |
|
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion.
|
|
Read more...
|
|
Monday, 17 October 2011 20:26 |
|
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updates to its development program for IPI-926, including that the company has completed enrollment of its Phase 2 trial of IPI-926 in patients with previously untreated pancreatic cancer.
|
|
Read more...
|
|
Monday, 17 October 2011 20:23 |
|
AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in the treatment of patients with relapsing multiple myeloma who received one previous therapy.
|
|
Read more...
|
|
Saturday, 15 October 2011 16:53 |
|
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease.
|
|
Read more...
|
|
Saturday, 15 October 2011 16:50 |
|
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has completed the treatment phase of the Ampion-in-Knee (AIK) trial.
|
|
Read more...
|
|
Saturday, 15 October 2011 00:21 |
|
Atrium Medical Corporation (Hudson, NH) announced that Principal Investigator Prof. Bibombe Patrice Mwipatayi, MMed (Surg), published results from the COBEST (Covered Versus Balloon-Expandable Stent Trial) trial online ahead of print in the Journal of Vascular Surgery.
|
|
Read more...
|
|
Friday, 14 October 2011 01:41 |
|
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib: Results of a Multicenter Phase 1/2 Trial" reporting Phase 1/2 combination activity of perifosine in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 10, 2011 online edition of the Journal of Clinical Oncology (JCO).
|
|
Read more...
|
|
Friday, 14 October 2011 01:18 |
|
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
|
|
Read more...
|
|
Thursday, 13 October 2011 00:50 |
|
Pfizer negotiated exclusive worldwide rights to develop GlycoMimetics’ pan-selectin antagonist GMI-1070, in a deal which could be worth $340 million to GlycoMimetics in up-front and development, regulatory, and commercialization milestones, plus additional sale royalties.
|
|
Read more...
|
|
